Healthcare Unfiltered Express

Episode 57: The KOMET-007 Trial

19 min · Gestern
Episode Episode 57: The KOMET-007 Trial Cover

Beschreibung

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.  A must listen - please share subscribe, and join the conversation.

Kommentare

0

Sei die erste Person, die kommentiert

Melde dich jetzt an und werde Teil der Healthcare Unfiltered Express-Community!

Loslegen

2 Monate für 1 €

Dann 4,99 € / Monat · Jederzeit kündbar.

  • Podcasts nur bei Podimo
  • 20 Stunden Hörbücher / Monat
  • Alle kostenlosen Podcasts

Alle Folgen

57 Folgen